explicit_doi,bibref,retrieved_local_doi,retrieved_remote_doi,manual_doi
10.1016/j.jsbmb.2013.05.011,"Gupta, A, Kumar, SB, Negi, AS. Current status on development of steroids as anticancer agents. J Steroid Biochem Mol Biol 2013; 137: 242–70. PMID: 23727548",10.1016/j.jsbmb.2013.05.011,10.1016/j.jsbmb.2013.05.011,10.1016/j.jsbmb.2013.05.011
,"Butenandt, A, Wolff, A, Karlson, P. Über Lumi-oestron. Chem Ber 1941; 74: 1308–12.",10.1002/cber.19410740724,10.1002/cber.19410740724,10.1002/cber.19410740724
,"Yaremenko, FG, Khvat, AV. A new one-pot synthesis of 17-oxo-13α-steroids of the androstane series from their 13β-analogues. Mendeleev Commun 1994; 187: 187–8.",10.1070/mc1994v004n05abeh000409,10.1070/mc1994v004n05abeh000409,10.1070/mc1994v004n05abeh000409
10.1016/j.jsbmb.2011.07.009,"Ayan, D, Roy, J, Maltais, R, Poirier, D. Impact of estradiol structural modifications (18-methyl and/or 17-hydroxy inversion of configuration) on the in vitro and in vivo estrogenic activity. J Steroid Biochem Mol Biol 2011; 127: 324–30. PMID: 21827856",10.1016/j.jsbmb.2011.07.009,10.1016/j.jsbmb.2011.07.009,10.1016/j.jsbmb.2011.07.009
10.1021/jo000108x,"Schönecker, B, Lange, C, Kötteritzsch, M, et al. Conformational design for 13α-steroids. J Org Chem 2000; 65: 5487–97. PMID: 10970286",10.1021/jo000108x,10.1021/jo000108x,10.1021/jo000108x
10.1016/j.ejmech.2014.09.051,"Kaur, R, Kaur, G, Kaur Gill, R, et al. Recent developments in tubulin polymerization inhibitors: an overview. Eur J Med Chem 2014; 87: 89–124. PMID: 25240869",10.1016/j.ejmech.2014.09.051,10.1016/j.ejmech.2014.09.051,10.1016/j.ejmech.2014.09.051
10.1016/j.tcb.2018.05.001,"Steinmetz, MO, Prota, AE. Microtubule-targeting agents: strategies to hijack the cytoskeleton. Trends Cell Biol 2018; 28: 776–92. PMID: 29871823",10.1016/j.tcb.2018.05.001,10.1016/j.tcb.2018.05.001,10.1016/j.tcb.2018.05.001
10.1016/j.ejmech.2019.03.025,"Naaz, F, Haider, MR, Shafi, S, Yar, MS. Anti-tubulin agents of natural origin: targeting taxol, vinca, and colchicine binding domains. Eur J Med Chem 2019; 171: 310–31. PMID: 30953881",10.1016/j.ejmech.2019.03.025,10.1016/j.ejmech.2019.03.025,10.1016/j.ejmech.2019.03.025
10.1016/j.ejmech.2017.11.062,"Cao, YN, Zheng, LL, Wang, D, et al. Recent advances in microtubule-stabilizing agents. Eur J Med Chem 2018; 143: 806–28. PMID: 29223097",10.1016/j.ejmech.2017.11.062,10.1016/j.ejmech.2017.11.062,10.1016/j.ejmech.2017.11.062
10.1016/j.chembiol.2013.01.014,"Field, JJ, Díaz, JF, Miller, JH. The binding sites of microtubule-stabilizing agents. Chem Biol 2013; 20: 301–15. PMID: 23521789",10.1016/j.chembiol.2013.01.014,10.1016/j.chembiol.2013.01.014,10.1016/j.chembiol.2013.01.014
10.4155/fmc-2017-0100,"Li, W, Sun, H, Xu, S, et al. Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures. Future Med Chem 2017; 9: 1765–94. PMID: 28929799",10.4155/fmc-2017-0100,10.4155/fmc-2017-0100,10.4155/fmc-2017-0100
10.1021/ml200149g,"Beale, TM, Allwood, DM, Bender, A, et al. A-ring dihalogenation increases the cellular activity of combretastatin templated tetrazoles. ACS Med Chem Lett 2012; 3: 177–81. PMID: 24900453",10.1021/ml200149g,10.1021/ml200149g,10.1021/ml200149g
,"Liang, L, Astruc, D. The copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC) “click” reaction and its applications. An overview. Coord Chem Rev 2011; 255: 2933–45.",10.1016/j.ccr.2011.06.028,10.1016/j.ccr.2011.06.028,10.1016/j.ccr.2011.06.028
,"Szabó, J, Jerkovics, N, Schneider, G, et al. Synthesis and in vitro antiproliferative evaluation of C-13 epimers of triazolyl-d-secoestrone alcohols: the first potent 13α-d-secoestrone derivative. Molecules 2016; 21: 611–24.",10.3390/molecules21050611,10.3390/molecules21050611,10.3390/molecules21050611
10.1016/j.jsbmb.2016.06.013,"Bózsity, N, Minorics, R, Szabó, J, et al. Mechanism of antiproliferative action of a new d-secoestrone-triazole derivative in cervical cancer cells and its effect on cancer cell motility. J Steroid Biochem Mol Biol 2017; 165: 247–57. PMID: 27363663",10.1016/j.jsbmb.2016.06.013,10.1016/j.jsbmb.2016.06.013,10.1016/j.jsbmb.2016.06.013
10.1016/j.steroids.2016.05.010,"Szabó, J, Pataki, Z, Wölfling, J, et al. Synthesis and biological evaluation of 13α-estrone derivatives as potential antiproliferative agents. Steroids 2016; 113: 14–21. PMID: 27263437",10.1016/j.steroids.2016.05.010,10.1016/j.steroids.2016.05.010,10.1016/j.steroids.2016.05.010
10.1080/14756366.2018.1490731,"Bacsa, I, Herman, BE, Jójárt, R, et al. Synthesis and structure-activity relationships of 2-and/or 4-halogenated 13β-and 13α-estrone derivatives as enzyme inhibitors of estrogen biosynthesis. J Enzyme Inhib Med Chem 2018; 33: 1271–82. PMID: 30230387",10.1080/14756366.2018.1490731,10.1080/14756366.2018.1490731,10.1080/14756366.2018.1490731
10.3762/bjoc.14.262,"Jójárt, R, Pécsy, S, Keglevich, G, et al. Pd-catalyzed microwave-assisted synthesis of phosphonated 13α-estrones as potential OATP2B1, 17β-HSD1 and/or STS inhibitors. Beilstein J Org Chem 2018; 14: 2838–45. PMID: 30498534",10.3762/bjoc.14.262,10.3762/bjoc.14.262,10.3762/bjoc.14.262
,"Hirao, T, Masunaga, T, Ohshiro, Y, Agawa, T. Stereoselective synthesis of vinylphosphonate. Tetrahedron Lett 1980; 21: 3595–8.",10.1016/0040-4039(80)80245-0,10.1016/0040-4039(80)80245-0,10.1016/0040-4039(80)80245-0
,"Keglevich, G, Jablonkai, E, László, BB. A “green” variation of the Hirao reaction: the P-C coupling of diethyl phosphite, alkyl phenyl-H-phosphinates and secondary phosphine oxides with bromoarenes using a P-ligand-free Pd(OAc) 2 catalyst under micro-wave and solvent-free conditions. RSC Adv 2014; 4: 22808–16.",10.1039/c4ra03292f,10.1039/c4ra03292f,10.1039/c4ra03292f
10.1021/acs.joc.6b00220,"Dziuganowska, ZA, Ślepokura, K, Volle, JN, et al. Structural analogues of Selfotel (CGS-19755). J Org Chem 2016; 81: 4947–54. PMID: 27187758",10.1021/acs.joc.6b00220,10.1021/acs.joc.6b00220,10.1021/acs.joc.6b00220
10.1002/adsc.201700895,"Keglevich, G, Henyecz, R, Mucsi, Z, Kiss, NZ. The palladium acetate-catalyzed microwave-assisted Hirao reaction without an added phosphorus ligand as a “green” protocol: a quantum chemical study on the mechanism. Adv Synth Catal 2017; 359: 4322–31. PMID: 29399016",10.1002/adsc.201700895,10.1002/adsc.201700895,10.1002/adsc.201700895
10.1016/j.dmpk.2014.10.005,"Matsumoto, J, Ariyoshi, N, Sakakibara, M, et al. Organic anion transporting polypeptide 2B1 expression correlates with uptake of estrone-3-sulfate and cell proliferation in estrogen receptor-positive breast cancer cells. Drug Metab Pharmacokinet 2015; 30: 133–41. PMID: 25857231",10.1016/j.dmpk.2014.10.005,10.1016/j.dmpk.2014.10.005,10.1016/j.dmpk.2014.10.005
10.1124/jpet.112.192344,"Banerjee, N, Allen, C, Bendayan, R. Differential role of organic anion-transporting polypeptides in estrone-3-sulphate uptake by breast epithelial cells and breast cancer cells. J Pharmacol Exp Ther 2012; 342: 510–09. PMID: 22588260",10.1124/jpet.112.192344,10.1124/jpet.112.192344,10.1124/jpet.112.192344
10.1016/j.steroids.2014.05.015,"Mernyák, E, Szabó, J, Bacsa, I, et al. Syntheses and antiproliferative effects of D-homo-and D-secoestrones. Steroids 2014; 87: 128–36. PMID: 24928727",10.1016/j.steroids.2014.05.015,10.1016/j.steroids.2014.05.015,10.1016/j.steroids.2014.05.015
10.2174/092986712802430072,"Peyrat, J-F, Brion, J-D, Alami, M. Synthetic 2-methoxyestradiol derivatives: structure-activity relationships. Curr Med Chem 2012; 19: 4142–56. PMID: 22709003",10.2174/092986712802430072,10.2174/092986712802430072,10.2174/092986712802430072
10.1016/0022-1759(83)90303-4,"Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and citotoxicity assays. J Immunol Methods 1983; 65: 55–63. PMID: 6606682",10.1016/0022-1759(83)90303-4,10.1016/0022-1759(83)90303-4,10.1016/0022-1759(83)90303-4
10.1021/jm0306430,"Friesner, RA, Banks, JL, Murphy, RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004; 47: 1739–49. PMID: 15027865",10.1021/jm0306430.s001,10.1021/jm0306430.s001,10.1021/jm0306430 
10.1021/jm030644s,"Halgren, TA, Murphy, RB, Friesner, RA, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004; 47: 1750–9. PMID: 15027866",10.1021/jm030644s,10.1021/jm030644s,10.1021/jm030644s
,"Schrödinger Release 2019-4: Schrödinger, LLC, New York, NY, 2019.",10.1186/s13661-019-1279-9,10.1007/978-3-030-30545-1_21,???
10.1093/nar/28.1.235,"Berman, HM, Westbrook, J, Feng, Z, et al. The protein data bank. Protein Data Bank Nucleic Acids Res 2000; 28: 235–42. PMID: 10592235",10.1093/nar/28.1.235,10.2210/rcsb_pdb/pdb-cit-anal-2017,10.1093/nar/28.1.235
,"Sastry, GM, Adzhigirey, M, Day, T, et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aid Mol Des 2013; 27: 221–34.",10.1007/s10822-013-9644-8,10.1007/s10822-013-9644-8,10.1007/s10822-013-9644-8
,"Schrödinger Release 2019-4: Maestro, Schrödinger, LLC, New York, NY; 2019.",10.1186/s13661-019-1279-9,10.1007/978-3-030-30545-1_21,???
,"Bowers, KJ, Chow, E, Xu, H, et al, Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters. Proceedings of the ACM/IEEE Conference on Supercomputing (SC06), Tampa, FL, 2006, November 11–17.",10.1145/1188455.1188544,10.1145/1188455.1188544,10.1145/1188455.1188544
,"Schrödinger Release 2019-4: Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2019.",10.1111/ajt.15169,10.3934/jmd.2019009,???
10.1021/acs.jctc.5b00864,"Harder, E, Damm, W, Maple, J, et al. OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. J Chem Theory Comput 2016; 12: 281–96. PMID: 26584231",10.1021/acs.jctc.5b00864.s001,10.1021/acs.jctc.5b00864.s001,10.1021/acs.jctc.5b00864
,"Hoover, WG. Canonical dynamics: equilibrium phase-space distributions. Phys Rev A 1985; 31: 1695–7.",10.1103/physreva.31.1695,10.1103/physreva.31.1695,10.1103/physreva.31.1695
10.1038/nrd.2018.21,"Ferguson, FM, Gray, NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov 2018; 17: 353–77. PMID: 29545548",10.1038/nrd.2018.21,10.1038/nrd.2018.21,10.1038/nrd.2018.21
10.1186/s12943-018-0804-2,"Bhullar, KS, Lagaron, NO, McGowan, EM, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer 2018; 17: 48. PMID: 29455673",10.1186/s12943-018-0804-2,10.1186/s12943-018-0804-2,10.1186/s12943-018-0804-2
10.1016/j.tips.2015.04.005,"Wu, P, Nielsen, TE, Clausen, MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci 2015; 36: 422–39. PMID: 25975227",10.1016/j.tips.2015.04.005,10.1016/j.tips.2015.04.005,10.1016/j.tips.2015.04.005
10.1016/j.phrs.2019.104609,"Roskoski, R, Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol Res 2020; 152: 104609. PMID: 31862477",10.1016/j.phrs.2019.104609,10.1016/j.phrs.2019.104609,10.1016/j.phrs.2019.104609
10.1016/j.currproblcancer.2013.06.001,"Jeong, W, Doroshow, JH, Kummar, S. United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies. Curr Probl Cancer 2013; 37: 110–44. PMID: 23972982",10.1016/j.currproblcancer.2013.06.001,10.1016/j.currproblcancer.2013.06.001,10.1016/j.currproblcancer.2013.06.001
10.1021/acs.jmedchem.8b01469,"Tadesse, S, Caldon, EC, Tilley, W, Wang, S. Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update. J Med Chem 2019; 62: 4233–51. PMID: 30543440",10.1021/acs.jmedchem.8b01469,10.1021/acs.jmedchem.8b01469,10.1021/acs.jmedchem.8b01469
,"Tsai, LH, Lees, E, Faha, B, et al. The cdk2 kinase is required for the G1-to-S transition in mammalian cells. Oncogene 1993; 8: 1593–602. PMID: 8502482",10.1016/s0960-9822(99)80191-2,10.1038/sj.onc.1201400,???
10.1073/pnas.90.3.1112,"Keyomarsi, K, Pardee, AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A 1993; 90: 1112–6. PMID: 8430082",10.1073/pnas.90.3.1112,10.1073/pnas.90.3.1112,10.1073/pnas.90.3.1112
10.18632/oncotarget.4600,"Yang, L, Fang, D, Chen, H, et al. Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression. Oncotarget 2015; 6: 20801–12. PMID: 26204491",10.18632/oncotarget.4600,10.18632/oncotarget.4600,10.18632/oncotarget.4600
10.3892/ijo.13.2.233,"Yamamoto, H, Monden, T, Miyoshi, H, et al. Cdk2/cdc2 expression in colon carcinogenesis and effects of cdk2/cdc2 inhibitor in colon cancer cells. Int J Oncol 1998; 13: 233–9. PMID: 9664116",10.3892/ijo.13.2.233,10.3892/ijo.13.2.233,10.3892/ijo.13.2.233
10.1016/j.tranon.2016.08.007,"Wang, J, Yang, T, Xu, G, et al. Cyclin-dependent kinase 2 promotes tumor proliferation and induces radio resistance in glioblastoma. Transl Oncol 2016; 9: 548–56. PMID: 27863310",10.1016/j.tranon.2016.08.007,10.1016/j.tranon.2016.08.007,10.1016/j.tranon.2016.08.007
10.4161/cc.6.23.4994,"Faber, AC, Chiles, TC. Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas. Cell Cycle 2007; 6: 2982–9. PMID: 18156799",10.4161/cc.6.23.4994,10.4161/cc.6.23.4994,10.4161/cc.6.23.4994
10.2217/fon-2017-0561,"Yin, X, Yu, J, Zhou, Y, et al. Identification of CDK2 as a novel target in treatment of prostate cancer. Future Oncol 2018; 14: 709–18. PMID: 29323532",10.2217/fon-2017-0561,10.2217/fon-2017-0561,10.2217/fon-2017-0561
10.3389/fonc.2018.00303,"Lin, ZP, Zhu, YL, Ratner, ES. Targeting cyclin-dependent kinases for treatment of gynecologic cancers. Front Oncol 2018; 8: 303. PMID: 30135856",10.3389/fonc.2018.00303,10.3389/fonc.2018.00303,10.3389/fonc.2018.00303
10.1186/1476-4598-3-1,"Hamdouchi, C, Keyser, H, Collins, E, et al. The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines. Mol Cancer Ther 2004; 3: 1–9. PMID: 14749470",10.1002/chin.200516223,10.1002/chin.200516223,???
10.1021/jm800382h,"Wyatt, PG, Woodhead, AJ, Berdini, V, et al. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J Med Chem 2008; 51: 4986–99. PMID: 18656911",10.2210/pdb2vta/pdb,10.2210/pdb2vtp/pdb,10.2210/pdb2vtp/pdb
10.1080/10428194.2016.1239259,"Seftel, MD, Kuruvilla, J, Kouroukis, T, et al. The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group. Leuk Lymphoma 2017; 58: 1358–65. PMID: 27750483",10.1080/10428194.2016.1239259,10.1080/10428194.2016.1239259,10.1080/10428194.2016.1239259
10.1016/j.ejmech.2020.112073,"Cheng, C, Yun, F, Ullah, S, Yuan, Q. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity. Eur J Med Chem 2020; 189: 112073. PMID: 31991336",10.1016/j.ejmech.2020.112073,10.1016/j.ejmech.2020.112073,10.1016/j.ejmech.2020.112073
10.1021/jm0103256,"Honma, T, Hayashi, K, Aoyama, T, et al. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem 2001; 44: 4615–27. PMID: 11741479",10.1021/jm0103256,10.1021/jm0103256,10.1021/jm0103256
10.1158/0008-5472.can-05-2507,"Payton, M, Chung, G, Yakowec, P, et al. Discovery and evaluation of dual CDK1 and CDK2 inhibitors. Cancer Res 2006; 66: 4299–308. PMID: 16618755",10.1158/0008-5472.can-05-2507,10.1158/0008-5472.can-05-2507,10.1158/0008-5472.can-05-2507
10.3109/14756366.2015.1057716,"Wróbel, TM, Kiełbus, M, Kaczor, AA, et al. Discovery of nitroaryl urea derivatives with antiproliferative properties. J Enzyme Inhib Med Chem 2016; 31: 608–18. PMID: 26114307",10.3109/14756366.2015.1057716,10.3109/14756366.2015.1057716,10.3109/14756366.2015.1057716
10.1021/acschembio.5b00398,"Alexander, LT, Möbitz, H, Drueckes, P, et al. Type II inhibitors targeting CDK2. ACS Chem Biol 2015; 10: 2116–25. PMID: 26158339",10.1021/acschembio.5b00398,10.1021/acschembio.5b00398,10.1021/acschembio.5b00398
10.1016/j.bioorg.2014.01.001,"Gouda, AM, Abdelazeem, AH, Arafa, e-SA, Abdellatif, KR. Design, synthesis and pharmacological evaluation of novel pyrrolizine derivatives as potential anticancer agents. Bioorg Chem 2014; 53: 1–7. PMID: 24462996",10.1016/j.bioorg.2014.01.001,10.1016/j.bioorg.2014.01.001,10.1016/j.bioorg.2014.01.001
10.1016/j.bmc.2017.08.039,"Gouda, AM, Abdelazeem, AH, Omar, HA, et al. Pyrrolizines: design, synthesis, anticancer evaluation and investigation of the potential mechanism of action. Bioorg Med Chem 2017; 25: 5637–51. PMID: 28916158",10.1016/j.bmc.2017.08.039,10.1016/j.bmc.2017.08.039,10.1016/j.bmc.2017.08.039
10.1016/j.ejmech.2019.111780,"Shawky, AM, Abourehab, MAS, Abdalla, AN, Gouda, AM. Optimization of pyrrolizine-based Schiff bases with 4-thiazolidinone motif: design, synthesis and investigation of cytotoxicity and anti-inflammatory potency. Eur J Med Chem 2020; 185: 111780. PMID: 31655429",10.1016/j.ejmech.2019.111780,10.1016/j.ejmech.2019.111780,10.1016/j.ejmech.2019.111780
10.1016/j.ejmech.2019.01.003,"Cheng, W, Yang, Z, Wang, S, et al. Recent development of CDK inhibitors: an overview of CDK/inhibitor co-crystal structures. Eur J Med Chem 2019; 164: 615–39. PMID: 30639897",10.1016/j.ejmech.2019.01.003,10.1016/j.ejmech.2019.01.003,10.1016/j.ejmech.2019.01.003
10.1016/j.ejmech.2017.07.067,"Tutone, M, Almerico, AM. Recent advances on CDK inhibitors: an insight by means of in silico methods. Eur J Med Chem 2017; 142: 300–15. PMID: 28802482",10.1016/j.ejmech.2017.07.067,10.1016/j.ejmech.2017.07.067,10.1016/j.ejmech.2017.07.067
,"Ece, A, Sevin, F. The discovery of potential cyclin A/CDK2 inhibitors: a combination of 3D QSAR pharmacophore modeling, virtual screening, and molecular docking studies. Med Chem Res 2013; 22: 5832–43.",10.1007/s00044-013-0571-y,10.1007/s00044-013-0571-y,10.1007/s00044-013-0571-y
,"Mohammad, T, Batra, S, Dahiya, R, et al. Identification of high-affinity inhibitors of cyclin-dependent kinase 2 towards anticancer therapy. Molecules 2019; 24: 4589.",10.3390/molecules24244589,10.3390/molecules24244589,10.3390/molecules24244589
10.1016/j.ejmech.2015.04.032,"Nakanishi, I, Murata, K, Nagata, N, et al. Identification of protein kinase CK2 inhibitors using solvent dipole ordering virtual screening. Eur J Med Chem 2015; 96: 396–404. PMID: 25912672",10.1016/j.ejmech.2015.04.032,10.1016/j.ejmech.2015.04.032,10.1016/j.ejmech.2015.04.032
10.1021/jm050468i,"Zhang, Q, Muegge, I. Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring. J Med Chem 2006; 49: 1536–48. PMID: 16509572",10.1021/jm050468i,10.1021/jm050468i,10.1021/jm050468i
10.1080/14756366.2019.1693702,"Liang, J-W, Wang, M-Y, Wang, S, et al. Identification of novel CDK2 inhibitors by a multistage virtual screening method based on SVM, pharmacophore and docking model. J Enzyme Inhib Med Chem 2020; 35: 235–44. PMID: 31760818",10.1080/14756366.2019.1693702,10.1080/14756366.2019.1693702,10.1080/14756366.2019.1693702
10.1007/s00894-012-1528-7,"Poulsen, A, William, A, Blanchard, S, et al. Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3). J Mol Model 2013; 19: 119–30. PMID: 22820730",10.1007/s00894-012-1528-7,10.1007/s00894-012-1528-7,10.1007/s00894-012-1528-7
10.1007/978-1-60761-839-3_11,"Horvath, D. Pharmacophore-based virtual screening. Methods Mol Biol 2011; 672: 261–98. PMID: 20838973",10.1007/978-1-60761-839-3_11,10.1007/978-1-60761-839-3_11,10.1007/978-1-60761-839-3_11
10.1016/j.bmcl.2015.08.050,"Hu, Y, Li, S, Liu, F, et al. Discovery of novel nonpeptide allosteric inhibitors interrupting the interaction of CDK2/cyclin A3 by virtual screening and bioassays. Bioorg Med Chem Lett 2015; 25: 4069–73. PMID: 26316466",10.1016/j.bmcl.2015.08.050,10.1016/j.bmcl.2015.08.050,10.1016/j.bmcl.2015.08.050
10.1093/nar/gkw287,"Sunseri, J, Koes, DR. Pharmit: interactive exploration of chemical space. Nucleic Acids Res 2016; 44: W442–8. PMID: 27095195",10.1093/nar/gkw287,10.1093/nar/gkw287,10.1093/nar/gkw287
,"Gouda, AM, Ali, HI, Almalki, WH, Azim, MA, et al. Design, synthesis, and biological evaluation of some novel pyrrolizine derivatives as COX inhibitors with anti-inflammatory/analgesic activities and low ulcerogenic liability. Molecules 2016; 21: 201.",10.3390/molecules21020201,10.3390/molecules21020201,10.3390/molecules21020201
10.1016/j.bioorg.2019.103371,"Attalah, KM, Abdalla, AN, Aslam, A, Ahmed, M, et al. Ethyl benzoate bearing pyrrolizine/indolizine moieties: design, synthesis and biological evaluation of anti-inflammatory and cytotoxic activities. Bioorg Chem 2020; 94: 103371. PMID: 31708230",10.1016/j.bioorg.2019.103371,10.1016/j.bioorg.2019.103371,10.1016/j.bioorg.2019.103371
10.2478/acph-2018-0026,"Gouda, AM, Abdelazeem, AH, Abdalla, AN, Ahmed, M. Pyrrolizine-5-carboxamides: exploring the impact of various substituents on anti-inflammatory and anticancer activities. Acta Pharm 2018; 68: 251–73. PMID: 31259695",10.2478/acph-2018-0026,10.2478/acph-2018-0026,10.2478/acph-2018-0026
,"Belal, A, Gouda, AM, Ahmed, AS, Abdel Gawad, NM. Synthesis of novel indolizine, diazepinoindolizine and pyrimidoindolizine derivatives as potent and selective anticancer agents. Res Chem Intermed 2015; 41: 9687–701.",10.1007/s11164-015-1958-9,10.1007/s11164-015-1958-9,10.1007/s11164-015-1958-9
,"Elsaady, MT, Gouda, AM, Edrees, FH, Gawad, NMA. Synthesis and biological evaluation of some novel Schiff base derivatives as potential anticancer agents. J Chem Pharm Res 2016; 8: 273–82.",10.1021/jm049213f.s001,10.1002/ardp.201000188,???
10.1016/j.ejmech.2018.04.029,"Malki, WH, Gouda, AM, Ali, HEA, et al. Structural-based design, synthesis, and antitumor activity of novel alloxazine analogues with potential selective kinase inhibition. Eur J Med Chem 2018; 152: 31–52. PMID: 29684708",10.1016/j.ejmech.2018.04.029,10.1016/j.ejmech.2018.04.029,10.1016/j.ejmech.2018.04.029
10.1016/j.jsps.2019.04.003,"Alkahtani, HM, Alanazi, MM, Aleanizy, FS, et al. Synthesis, anticancer, apoptosis-inducing activities and EGFR and VEGFR2 assay mechanistic studies of 5,5-diphenylimidazolidine-2,4-dione derivatives: molecular docking studies. Saudi Pharm J 2019; 27: 682–93. PMID: 31297023",10.1016/j.jsps.2019.04.003,10.1016/j.jsps.2019.04.003,10.1016/j.jsps.2019.04.003
,"Abdalla, AN, Shaheen, U, Abdallah, QMA, et al. Proapoptotic activity of Achillea membranacea essential oil and its major constituent 1,8-cineole against A2780 ovarian cancer cells. Molecules 2020; 25: 1582.",10.3390/molecules25071582,10.3390/molecules25071582,10.3390/molecules25071582
10.1016/j.bmc.2018.05.024,"Wang, Y, Chen, Y, Cheng, X, et al. Design, synthesis and biological evaluation of pyrimidine derivatives as novel CDK2 inhibitors that induce apoptosis and cell cycle arrest in breast cancer cells. Bioorg Med Chem 2018; 26: 3491–501. PMID: 29853338",10.1016/j.bmc.2018.05.024,10.1016/j.bmc.2018.05.024,10.1016/j.bmc.2018.05.024
10.1002/jcc.21256,"Morris, GM, Huey, R, Lindstrom, W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009; 30: 2785–91. PMID: 19399780",10.1002/jcc.21256,10.1002/jcc.21256,10.1002/jcc.21256
,"Gouda, AM, Almalki, FA. Carprofen: a theoretical mechanistic study to investigate the impact of hydrophobic interactions of alkyl groups on modulation of COX-1/2 binding selectivity. SN Appl Sci 2019; 1: 332.",10.1007/s42452-019-0335-5,10.1007/s42452-019-0335-5,10.1007/s42452-019-0335-5
,"Almalki, FA, Gouda, AM, Bin Ali, MH, Almehmadi, OM. Profens: a comparative molecular docking study into cyclooxygenase-1/2. Drug Invent Today 2019; 11: 480–7.",10.19045/bspab.2018.70070,10.1101/866152,???
,"Attallah, KM, Gouda, AM, Ibrahim, IT, Abouzeid, L. Design, synthesis, 99mTc labeling, and biological evaluation of a novel pyrrolizine derivative as potential anti-inflammatory agent. Radiochemistry 2017; 59: 630–8.",10.1134/s10663622170600121,10.1134/s10663622170600121,10.1134/s10663622170600121
,"Dassault Systems BIOVIA, Discovery studio visualizer, v16.1.0.15350. San Diego (CA): Dassault Systems; 2016.",10.1016/0261-3069(95)90038-1,10.1016/0261-3069(95)90038-1,???
10.1021/jm0600388,"Lu, H, Schulze-Gahmen, U. Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition. J Med Chem 2006; 49: 3826–31. PMID: 16789739",10.1021/jm0600388,10.1021/jm0600388,10.1021/jm0600388
10.1021/cb2004516,"Baumli, S, Hole, AJ, Noble, ME, Endicott, JA. The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508. ACS Chem Biol 2012; 7: 811–6. PMID: 22292676",10.1021/cb2004516,10.1021/cb2004516,10.1021/cb2004516
10.1038/srep42717,"Daina, A, Michielin, O, Zoete, V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017; 7: 42717. PMID: 28256516",10.1038/srep42717,10.1038/srep42717,10.1038/srep42717
,"Lipinski, CA, Lombardo, F, Dominy, BW, Feeney, PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997; 23: 3–25.",10.1016/s0169-409x(96)00423-1,10.1016/s0169-409x(96)00423-1,10.1016/s0169-409x(96)00423-1
10.1023/a:1020444330011,"Zhao, YH, Abraham, MH, Le, J, et al. Rate-limited steps of human oral absorption and QSAR studies. Pharm Res 2002; 19: 1446–57. PMID: 12425461",10.1023/a:1020444330011,10.1002/jps.1031,10.1023/a:1020444330011
10.1038/nrd842,"Atkins, JH, Gershell, LJ. Selective anticancer drugs. Nat Rev Drug Discov 2002; 1: 491–2. PMID: 12120255",10.1038/nrd842,10.1038/nrd842,10.1038/nrd842
10.1038/nrd4504,"Asghar, U, Witkiewicz, AK, Turner, NC, Knudsen, ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015; 14: 130–46. PMID: 25633797",10.1038/nrd4504,10.1038/nrd4504,10.1038/nrd4504
,"Wang, J, Urbán, L. The impact of early ADME profiling on drug discovery and development strategy. DDW Drug Discov World 2004; 5: 73–86.",10.1002/9780470921920.edm021,10.1002/9780470921920.edm021,???
10.1016/s1359-6446(01)01712-3,"Li, AP. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov Today 2001; 6: 357–66. PMID: 11267922",10.1016/s1359-6446(01)01712-3,10.1016/s1359-6446(01)01712-3,10.1016/s1359-6446(01)01712-3
10.2174/156802611794480927,"Gleeson, MP, Hersey, A, Hannongbua, S. In-silico ADME models: a general assessment of their utility in drug discovery applications. Curr Top Med Chem 2011; 11: 358–81. PMID: 21320065",10.2174/156802611794480927,10.2174/156802611794480927,10.2174/156802611794480927
10.2174/1389200218666170316094104,"Yan, G, Wang, X, Chen, Z, et al. In-silico ADME studies for new drug discovery: from chemical compounds to Chinese herbal medicines. Curr Drug Metab 2017; 18: 535–9. PMID: 28302029",10.2174/1389200218666170316094104,10.2174/1389200218666170316094104,10.2174/1389200218666170316094104
10.1016/s0140-6736(18)32203-7,"GBD 2017 Causes of Death Collaborators Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 10; 392(10159): 1736–8. PMID: 30496103",10.3410/f.725286838.793544011,10.1097/01.ogx.0000511935.64476.66,10.1016/s0140-6736(18)32203-7
10.1002/ccd.1810160103,"Campeau, L. Percutaneous radial artery approach for coronary angiography. Cathet Cardiovasc Diagn. 1989 janv; 16(1): 3–7. PMID: 2912567",10.1002/ccd.1810160103,10.1002/ccd.1810160103,10.1002/ccd.1810160103
10.1016/s0140-6736(11)60404-2,"Jolly, SS, Yusuf, S, Cairns, J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011 avr 23; 377(9775): 1409–1420. PMID: 21470671",10.1016/j.ycar.2012.01.034,10.1016/s0140-6736(11)60404-2,???
,"Babunashvili, A, Dundua, D. Recanalization and reuse of early occluded radial artery within 6 days after previous transradial diagnostic procedure. Catheterization Cardiovasc Interventions. 2011; 77(4): 530–536.",10.1002/ccd.22846,10.1002/ccd.22846,10.1002/ccd.22846
,"Kiemeneij, F. Left distal transradial access in the anatomical snuffbox for coronary angiography (ldTRA) and interventions (ldTRI) [Internet]. EuroIntervention. [ citéd 2019 10 12]. Disponible sur: https://eurointervention.pcronline.com/article/left-distal-transradial-access-in-the-anatomical-snuffbox-for-coronary-angiography-ldtra-and-interventions-ldtri",10.4244/eij-d-17-00079,10.4244/eij-d-17-00079,10.4244/eij-d-17-00079
,"Vefalı V, Sarıçam E. The Comparison of Traditional Radial Access and Novel Distal Radial Access for Cardiac Catheterization. Cardiovasc Revasc Med. 2020 Apr;21(4):496–500.",10.1016/j.carrev.2019.07.001,10.1016/j.carrev.2019.07.001,10.1016/j.carrev.2019.07.001
,"Koutouzis, M, Kontopodis, E, Tassopoulos, A, et al. Distal versus traditional radial approach for coronary angiography. Cardiovasc Revascularization Med. 2019 août 1; 20(8): 678–680.",10.1016/j.carrev.2018.09.018,10.1016/j.carrev.2018.09.018,10.1016/j.carrev.2018.09.018
10.1016/j.carrev.2020.03.020.,"Hamandi, M, Saad, M, Hasan, R, et al. Distal versus conventional transradial artery access for coronary angiography and intervention: A meta-analysis. Cardiovasc Revasc Med. 2020 Mars 14 DOI: DOI: 10.1016/j.carrev.2020.03.020.",10.1016/j.carrev.2020.03.020,10.1016/j.carrev.2020.03.020,10.1016/j.carrev.2020.03.020
,"Amin, MR, Singha, CK, Banerjee, SK, et al. Comparison of distal transradial in the anatomical snuffbox versus conventional transradial access for coronary angiography and intervention-an experience in 100 cases. Univ Heart J. 2017; 13(2): 40–45.",10.3329/uhj.v13i2.37657,10.3329/uhj.v13i2.37657,10.3329/uhj.v13i2.37657
,"Gajurel, RM, Sahi, R, Shrestha, H, et al. Initial experience on anatomical snuff box approach for coronary angiogram & percutaneous coronary intervention in a tertiary care center Nepal. World J Cardiovasc Dis. 2018 déc 28; 08(12): 578.",10.4236/wjcd.2018.812057,10.4236/wjcd.2018.812057,10.4236/wjcd.2018.812057
10.7759/cureus.7201,"Nairoukh, Z, Jahangir, S, Adjepong, D, et al. Distal radial artery access: the future of cardiovascular intervention. Cureus. 2020 3 7; 12(3): e7201. PMID: 32269880",10.7759/cureus.7201,10.7759/cureus.7201,10.7759/cureus.7201
,"Coomes, EA, Haghbayan, H, Cheema, AN. Distal transradial access for cardiac catheterization: a systematic scoping review. Catheterization Cardiovasc Interventions. citéd 2020 janv 30.",10.1002/ccd.28623,10.1002/ccd.28623,10.1002/ccd.28623
10.4244/eij-d-18-00635,"Lee, J-W, Park, SW, Son, J-W, et al. Real-world experience of the left distal transradial approach for coronary angiography and percutaneous coronary intervention: a prospective observational study (LeDRA). EuroIntervention. 2018 10 12; 14(9): e995–1003. PMID: 30222122",10.4244/eij-d-18-00635,10.4244/eij-d-18-00635,10.4244/eij-d-18-00635
10.1111/joic.12559,"Coughlan, JJ, Zebrauskaite, A, Arnous, S, et al. Left distal trans-radial access facilitates earlier discharge post-coronary angiography. J Interv Cardiol. 2018 déc; 31(6): 964–968. PMID: 30187577",10.1111/joic.12559,10.1111/joic.12559,10.1111/joic.12559
10.5114/aic.2019.83771,"Wretowski, D, Krakowian, M, Łabyk, A, et al. Very distal transradial approach (VITRO) for coronary interventions. Postepy Kardiol Interwencyjnej. 2019; 15(1): 42–45. PMID: 31043983",10.5114/aic.2019.83771,10.5114/aic.2019.83771,10.5114/aic.2019.83771
,"Kühn, AL, de Macedo Rodrigues, K, Singh, J, et al. Distal radial access in the anatomical snuffbox for neurointerventions: a feasibility, safety, and proof-of-concept study. J Neurointerv Surg. 2020 janv 8; 12(8): 798–801.",10.1136/neurintsurg-2019-015604,10.1136/neurintsurg-2019-015604,10.1136/neurintsurg-2019-015604
,"Hamon, M, Pristipino, C, Mario, CD, et al. Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European association of percutaneous cardiovascular interventions and working groups on acute cardiac care** and thrombosis of the European society of cardiology [Internet]. EuroIntervention. [ citéd 2019 11 5]. Disponible sur: https://eurointervention.pcronline.com/article/consensus-document-on-the-radial-approach-in-percutaneous-cardiovascular-interventions-position-paper-by-the-european-association-of-percutaneous-cardiovascular-interventions-and-working-groups-on-acute-cardiac-care-and-thrombosis-of-the-european-society-of-cardiology",10.4244/eijv8i11a192,10.4244/eijv8i11a192,10.4244/eijv8i11a192
10.1016/j.jcin.2011.08.011,"Uhlemann, M, Möbius-Winkler, S, Mende, M, et al. The leipzig prospective vascular ultrasound registry in radial artery catheterization: impact of sheath size on vascular complications. JACC Cardiovasc Interv. 2012 1 1; 5(1): 36–43. PMID: 22230148",10.1016/j.jcin.2011.08.011,10.1016/j.jcin.2011.08.011,10.1016/j.jcin.2011.08.011
10.1016/s0002-9149(98)00821-2,"Nagai, S, Abe, S, Sato, T, et al. Ultrasonic assessment of vascular complications in coronary angiography and angioplasty after transradial approach. Am J Cardiol. 1999 janv 15; 83(2): 180–186. PMID: 10073818",10.1016/s0002-9149(98)00821-2,10.1016/s0002-9149(98)00821-2,10.1016/s0002-9149(98)00821-2
,"Kaledin A, Kochanov IN, Podmetin PS, Seletsky SS, Ardeev VN. Distal radial artery in endovascular interventions; 2017.",10.1093/eurheartj/ehz746.0687,10.1177/1526602820963022,10.13140/RG.2.2.13406.33600
,"Mizuguchi, Y, Izumikawa, T, Hashimoto, S, et al. Efficacy and safety of the distal transradial approach in coronary angiography and percutaneous coronary intervention: a Japanese multicenter experience. Cardiovasc Interv Ther. 2019; 24.",10.1007/s12928-019-00590-0,10.1007/s12928-019-00590-0,10.1007/s12928-019-00590-0
,"Amin, MR, Banerjee, SK, Biswas, E, et al. Feasibility and safety of distal transradial access in the anatomical snuffbox for coronary angiography and intervention. Mymensingh Med J. 2019 juill; 28(3): 647–654. PMID: 31391439",10.3329/uhj.v13i2.37657,10.3329/uhj.v13i2.37657,???
,"Okuyan, H, Hzal, F, Taçoy, G, et al. Angiographic evaluation of the radial artery diameter in patients who underwent coronary angiography or coronary intervention. J Invasive Cardiol. 2013 juill; 25(7): 353–357. PMID: 23813065",10.1016/j.jacc.2013.08.666,10.1016/j.jacc.2013.08.666,10.1016/j.jacc.2013.08.666
,"Naito, T, Sawaoka, T, Sasaki, K, et al. Evaluation of the diameter of the distal radial artery at the anatomical snuff box using ultrasound in Japanese patients. Cardiovasc Interventions Ther [Internet] 2019 janv 7 [ citéd août 21]; Disponible sur; 34: 312–316.",10.1007/s12928-018-00567-5,10.1007/s12928-018-00567-5,10.1007/s12928-018-00567-5
,"Davis, BJ, Roughley, SD. Fragment-based lead discovery. Annu Rep Med Chem 2017; 50: 371–439.",10.1016/bs.armc.2017.07.002,10.1016/bs.armc.2017.07.002,10.1016/bs.armc.2017.07.002
10.1038/nchem.217,"Murray, CW, Rees, DC. The rise of fragment-based drug discovery. Nat Chem 2009; 1: 187–92. PMID: 21378847",10.1038/nchem.217,10.1038/nchem.217,10.1038/nchem.217
10.1007/s10858-013-9740-z,"Harner, MJ, Frank, AO, Fesik, SW. Fragment-based drug discovery using NMR spectroscopy. J Biomol NMR 2013; 56: 65–75. PMID: 23686385",10.1007/s10858-013-9740-z,10.1007/s10858-013-9740-z,10.1007/s10858-013-9740-z
,"Ma, R, Wang, P, Wu, J, Ruan, K. Process of fragment-based lead discovery –a perspective from NMR. Molecules 2016; 21: 854.",10.3390/molecules21070854,10.3390/molecules21070854,10.3390/molecules21070854
10.1021/jm200558u,"Verdonk, ML, Giangreco, I, Hall, RJ, et al. Docking performance of fragments and druglike compounds. J Med Chem 2011; 54: 5422–31. PMID: 21692478",10.1021/jm200558u,10.1021/jm200558u,10.1021/jm200558u
10.2174/156802612804547371,"Mortier, J, Rakers, C, Frederick, R, Wolber, G. Computational tools for in silico fragment-based drug design. Curr Top Med Chem 2012; 12: 1935–43. PMID: 23116473",10.2174/156802612804547371,10.2174/156802612804547371,10.2174/156802612804547371
10.1111/j.1582-4934.2008.00665.x,"Zoete, V, Grosdidier, A, Michielin, O. Docking, virtual high throughput screening and in silico fragment-based drug design. J Cell Mol Med 2009; 13: 238–48. PMID: 19183238",10.1111/j.1582-4934.2008.00665.x,10.1111/j.1582-4934.2008.00665.x,10.1111/j.1582-4934.2008.00665.x
10.1021/jm00067a013,"Caflisch, A, Miranker, A, Karplus, M. Multiple copy simultaneous search and construction of ligands in binding sites: application to inhibitors of HIV-1 aspartic proteinase. J Med Chem 1993; 36: 2142–67. PMID: 8340918",10.1021/jm00067a013,10.1021/jm00067a013,10.1021/jm00067a013
10.1021/acs.jcim.7b00625,"Martinez-Rosell, G, Harvey, MJ, De Fabritiis, G. Molecular-simulation-driven fragment screening for the discovery of new CXCL12 inhibitors. J Chem Inf Model 2018; 58: 683–91. PMID: 29481075",10.1021/acs.jcim.7b00625,10.1021/acs.jcim.7b00625,10.1021/acs.jcim.7b00625
10.1021/acs.jctc.9b00069,"Linker, SM, Magarkar, A, Köfinger, J, et al. Fragment binding pose predictions using unbiased simulations and Markov-state models. J Chem Theory Comput 2019; 15: 4974–81. PMID: 31402652",10.1021/acs.jctc.9b00069,10.1021/acs.jctc.9b00069,10.1021/acs.jctc.9b00069
10.1021/ci400766b,"Sabbadin, D, Moro, S. Supervised molecular dynamics (SuMD) as a helpful tool to depict GPCR-ligand recognition pathway in a nanosecond time scale. J Chem Inf Model 2014; 54: 372–6. PMID: 24456045",10.1021/ci400766b,10.1021/ci400766b,10.1021/ci400766b
10.1021/acs.jcim.5b00702,"Cuzzolin, A, Sturlese, M, Deganutti, G, et al. Deciphering the complexity of ligand-protein recognition pathways using supervised molecular dynamics (SuMD) simulations. J Chem Inf Model 2016; 56: 687–705. PMID: 27019343",10.1021/acs.jcim.5b00702,10.1021/acs.jcim.5b00702,10.1021/acs.jcim.5b00702
10.1016/j.str.2017.02.009,"Salmaso, V, Sturlese, M, Cuzzolin, A, Moro, S. Exploring protein-peptide recognition pathways using a supervised molecular dynamics approach. Structure 2017; 25: 655–62.e2. PMID: 28319010",10.1016/j.str.2017.02.009,10.1016/j.str.2017.02.009,10.1016/j.str.2017.02.009
10.1038/nature03579,"Oltersdorf, T, Elmore, SW, Shoemaker, AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677–81. PMID: 15902208",10.3410/f.1026512.327607,10.1038/nature03579,10.1038/nature03579
10.1038/nrd.2016.253,"Ashkenazi, A, Fairbrother, WJ, Leverson, JD, Souers, AJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov 2017; 16: 273–84. PMID: 28209992",10.1038/nrd.2016.253,10.1038/nrd.2016.253,10.1038/nrd.2016.253
10.1016/j.compbiolchem.2018.08.007,"Maity, A, Majumdar, S, Ghosh Dastidar, S. Flexibility enables to discriminate between ligands: Lessons from structural ensembles of Bcl-xl and Mcl-1. Comput Biol Chem 2018; 77: 17–27. PMID: 30195235",10.1016/j.compbiolchem.2018.08.007,10.1016/j.compbiolchem.2018.08.007,10.1016/j.compbiolchem.2018.08.007
10.1371/journal.pone.0064400,"Aguirre, C, ten Brink, T, Walker, O, et al. BcL-xL conformational changes upon fragment binding revealed by NMR. PLoS One 2013; 8: e64400. PMID: 23717610",10.1371/journal.pone.0064400,10.1371/journal.pone.0064400,10.1371/journal.pone.0064400
10.1016/b978-0-12-381274-2.00003-0,"Böttcher, J, Jestel, A, Kiefersauer, R, et al. Key factors for successful generation of protein-fragment structures: requirement on protein, crystals, and technology. Methods Enzymol 2011; 493: 61–89. PMID: 21371587",10.1016/b978-0-12-381274-2.00003-0,10.1016/b978-0-12-381274-2.00003-0,10.1016/b978-0-12-381274-2.00003-0
10.1038/381335a0,"Muchmore, SW, Sattler, M, Liang, H, et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996; 381: 335–41. PMID: 8692274",10.1038/381335a0,10.1038/381335a0,10.1038/381335a0
,"Molecular Operating Environment (MOE), 2019.01; Chemical Computing Group ULC, 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2020.",10.1162/comj.2001.25.1.95a,10.3866/pku.whxb201903057,???
,"Case, DA, Babin, V, Berryman, J, et al. Amber 14. Univ California, San Fr. n.d.",10.3103/s0027132220020084,10.21236/ada482672,???
10.1002/jcc.20035,"Wang, J, Wolf, RM, Caldwell, JW, Kollman, PA, et al. Development and testing of a general amber force field. J Comput Chem 2004; 25: 1157–74. PMID: 15116359",10.1002/jcc.20035,10.1002/jcc.20035,10.1002/jcc.20035
10.1093/nar/28.1.235,"Berman, HM, Westbrook, J, Feng, Z, et al. The protein data bank. Nucleic Acids Res 2000; 28: 235–42. PMID: 10592235",10.1093/nar/28.1.235,10.2210/rcsb_pdb/pdb-cit-anal-2017,10.1093/nar/28.1.235
10.1110/ps.9.12.2528,"Petros, AM, Nettesheim, DG, Wang, Y, et al. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci 2000; 9: 2528–34. PMID: 11206074",10.1017/s096183680000331x,10.1110/ps.9.12.2528,10.1017/s096183680000331x
,"Labute, P. Protonate 3D: assignment of macromolecular protonation state and geometry. Chem Comput Gr. 2007: 1–17.",10.1186/1752-153x-2-s1-s13,10.1186/1752-153x-2-s1-s13,10.1002/prot.22234
,"Case, D, Babin, V, Berryman, J, et al. Amber14, version AMBER14. San Francisco: University of California. 2014 Available from: http://ambermd.org/ [last accessed Oct 2015].",10.1021/acs.langmuir.9b01367.s001,10.1108/09504120710719644,10.13140/RG.2.2.17892.37766
10.1016/j.jmgm.2005.12.005,"Wang, J, Wang, W, Kollman, PA, Case, DA. Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Model 2006; 25: 247–60. PMID: 16458552",10.1016/j.jmgm.2005.12.005,10.1016/j.jmgm.2005.12.005,10.1016/j.jmgm.2005.12.005
,"Jakalian, A, Bush, BL, Jack, DB, Bayly, CI. Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: I. Method. J Comput Chem 2000; 21: 132–46.",10.1002/(sici)1096-987x(20000130)21:2<132::aid-jcc5>3.0.co;2-p,10.1002/(sici)1096-987x(20000130)21:2<132::aid-jcc5>3.0.co;2-p,10.1002/(sici)1096-987x(20000130)21:2<132::aid-jcc5>3.0.co;2-p
10.1002/jcc.10128,"Jakalian, A, Jack, DB, Bayly, CI. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J Comput Chem 2002; 23: 1623–41. PMID: 12395429",10.1002/jcc.10128,10.1002/jcc.10128,10.1002/jcc.10128
,"Berendsen, HJC, Postma, JPM, van Gunsteren, WF, et al. Molecular dynamics with coupling to an external bath. J Chem Phys 1984; 81: 3684–90.",10.1063/1.448118,10.1063/1.448118,10.1063/1.448118
10.1093/bioinformatics/btr168,"Bakan, A, Meireles, LM, Bahar, I. ProDy: protein dynamics inferred from theory and experiments. Bioinformatics 2011; 27: 1575–7. PMID: 21471012",10.1093/bioinformatics/btr168,10.1093/bioinformatics/btr168,10.1093/bioinformatics/btr168
,"Ester, M, Kriegel, HP, Sander, J, Xu, X. A density-based algorithm for discovering clusters in large spatial databases with noise. In: Proceedings of the 2nd International Conference on Knowledge Discovery and Data Mining. Portland: AAAI press. 1996: 226–231.",10.1109/icde.1998.655795,10.1109/icde.1998.655795,10.1.1.121.9220
,"Pedregosa, F, Varoquaux, GG, Gramfort, A, Michel, V, et al. Scikit-learn: machine learning in Python. J Mach Learn Res 2011; 12: 2825–30.",10.3389/fninf.2014.00014,10.1002/9781119557500.ch5,10.5555/1953048.2078195
,"Humphrey, W, Dalke, A, Schulten, K. VMD: visual molecular dynamics. J Mol Graph 1996; 14: 3333–8.",10.1016/0263-7855(96)00018-5,10.1016/0263-7855(96)00018-5,10.1016/0263-7855(96)00018-5
,"Hunter, JD. Matplotlib: a 2D graphics environment. Comput Sci Eng 2007; 9: 90–5.",10.1109/mcse.2007.55,10.1109/mcse.2007.55,10.1109/MCSE.2007.55
10.1007/s10858-005-4425-x,"Schanda, P, Kupce, E, Brutscher, B. SOFAST-HMQC experiments for recording two-dimensional heteronuclear correlation spectra of proteins within a few seconds. J Biomol NMR 2005; 33: 199–211. PMID: 16341750",10.1007/s10858-005-4425-x,10.1007/s10858-005-4425-x,10.1007/s10858-005-4425-x
10.1021/acs.jproteome.6b00121,"Stark, JL, Eghbalnia, HR, Lee, W, et al. NMRmix: a tool for the optimization of compound mixtures in 1D (1)H NMR ligand affinity screens. J Proteome Res 2016; 15: 1360–8. PMID: 26965640",10.1021/acs.jproteome.6b00121,10.1021/acs.jproteome.6b00121.s001,10.1021/acs.jproteome.6b00121
10.1093/nar/gkm957,"Ulrich, EL, Akutsu, H, Doreleijers, JF, et al. BioMagResBank. Nucleic Acids Res 2008; 36: D402–8. PMID: 17984079",10.1093/nar/gkm957,10.1093/nar/gkm957,10.1093/nar/gkm957
10.1016/j.pnmrs.2013.02.001,"Williamson, MP. Using chemical shift perturbation to characterise ligand binding. Prog Nucl Magn Reson Spectrosc 2013; 73: 1–16. PMID: 23962882",10.1016/j.pnmrs.2014.05.001,10.1016/j.pnmrs.2014.05.001,10.1016/j.pnmrs.2014.05.001
,"Mayer, M, Meyer, B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew Chem Int Ed 1999; 38: 1784–8.",10.1002/(sici)1521-3773(19990614)38:12<1784::aid-anie1784>3.0.co;2-q,10.1002/(sici)1521-3773(19990614)38:12<1784::aid-anie1784>3.0.co;2-q,10.1002/(sici)1521-3773(19990614)38:12<1784::aid-anie1784>3.0.co;2-q
10.1023/a:1013302231549,"Dalvit, C, Fogliatto, G, Stewart, A, et al. WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability. J Biomol NMR 2001; 21: 349–59. PMID: 11824754",10.1023/a:1013302231549,EXCEPTION: 'title',10.1023/a:1013302231549
,"Hwang, TL, Shaka, AJ. Water suppression that works. excitation sculpting using arbitrary wave-forms and pulsed-field gradients. J Magn Reson Ser A 1995; 112: 275–9.",10.1006/jmra.1995.1047,10.1006/jmra.1995.1047,10.1006/jmra.1995.1047
10.1093/bioinformatics/btu830,"Lee, W, Tonelli, M, Markley, JL. NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy. Bioinformatics 2015; 31: 1325–7. PMID: 25505092",10.1093/bioinformatics/btu830,10.1093/bioinformatics/btu830,10.1093/bioinformatics/btu830
,"Bienstock, RJ. Overview: fragment-based drug design In, Bienstock, RJ, ed. Library design, search methods, and applications of fragment-based drug design. Vol. 1076 ACS Symposium Series. Washington (DC): American Chemical Society; 2011: 1–26.",10.1021/bk-2011-1076.ch001,10.1021/bk-2011-1076.ch001,10.1021/bk-2011-1076.ch001
10.1021/jm100009z,"Barelier, S, Pons, J, Marcillat, O, et al. Fragment-based deconstruction of Bcl-xL inhibitors. J Med Chem 2010; 53: 2577–88. PMID: 20192224",10.1021/jm100009z,10.1021/jm100009z,10.1021/jm100009z
,"Ester, M, Kriegel, HP, Sander, J, Xu, X. A density-based algorithm for discovering clusters in large spatial databases with noise. KDD 1996; 96: 226–31.",10.1109/icde.1998.655795,10.1109/icde.1998.655795,???
10.1021/acs.jmedchem.8b01855,"Giordanetto, F, Jin, C, Willmore, L, et al. Fragment hits: what do they look like and how do they bind? J Med Chem 2019; 62: 3381–94. PMID: 30875465",10.1021/acs.jmedchem.8b01855,10.1021/acs.jmedchem.8b01855,10.1021/acs.jmedchem.8b01855
10.1021/ci200608b,"Ferenczy, GG, Keserű, GM. Thermodynamics of fragment binding. J Chem Inf Model 2012; 52: 1039–45. PMID: 22458364",10.1021/ci200608b,10.1021/ci200608b,10.1021/ci200608b
10.1023/a:1008354229396,"Dalvit, C, Pevarello, P, Tatò, M, et al. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J Biomol NMR 2000; 18: 65–8. PMID: 11061229",10.1023/a:1008354229396,EXCEPTION: 'title',10.1023/a:1008354229396
10.1016/j.pnmrs.2016.09.001,"Gossert, AD, Jahnke, W. NMR in drug discovery: a practical guide to identification and validation of ligands interacting with biological macromolecules. Prog Nucl Magn Reson Spectrosc 2016; 97: 82–125. PMID: 27888841",10.1016/j.pnmrs.2016.09.001,10.1016/j.pnmrs.2016.09.001,10.1016/j.pnmrs.2016.09.001
10.1021/jm0507532,"Petros, AM, Dinges, J, Augeri, DJ, et al. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem 2006; 49: 656–63. PMID: 16420051",10.1021/jm0507532.s001,10.1021/jm0507532.s001,10.1021/jm0507532
10.1074/jbc.m306021200,"Manion, MK, O'Neill, JW, Giedt, CD, et al. Bcl-XL mutations suppress cellular sensitivity to antimycin A. J Biol Chem 2004; 279: 2159–65. PMID: 14534311",10.1074/jbc.m306021200,10.1074/jbc.m306021200,10.1074/jbc.m306021200
10.1016/j.chembiol.2018.10.001,"Erlanson, DA, Davis, BJ, Jahnke, W. Fragment-based drug discovery: advancing fragments in the absence of crystal structures. Cell Chem Biol 2019; 26: 9–15. PMID: 30482678",10.1016/j.chembiol.2018.10.001,10.1016/j.chembiol.2018.10.001,10.1016/j.chembiol.2018.10.001
10.1177/1087057112465979,"Wielens, J, Headey, SJ, Rhodes, DI, et al. Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification? J Biomol Screen 2013; 18: 147–59. PMID: 23139382",10.1177/1087057112465979,10.1177/1087057112465979,10.1177/1087057112465979
10.1152/physrev.00038.2009,"Chudakov, DM, Matz, MV, Lukyanov, S, Lukyanov, KA. Fluorescent proteins and their applications in imaging living cells and tissues. Physiol Rev 2010; 90: 1103–63. PMID: 20664080",10.1152/physrev.00038.2009,10.1152/physrev.00038.2009,10.1152/physrev.00038.2009
10.1038/srep17740,"Liss, V, Barlag, B, Nietschke, M, Hensel, M. Self-labelling enzymes as universal tags for fluorescence microscopy, super-resolution microscopy and electron microscopy. Sci Rep 2015; 5: 17740–52. PMID: 26643905",10.1038/srep17740,10.1038/srep17740,10.1038/srep17740
,"Hatlem, D, Trunk, T, Linke, D, Leo, JC. Catching a SPY: using the SpyCatcher-SpyTag and related systems for labeling and localizing bacterial proteins. Int J Mol Sci 2019; 20: 2129–39.",10.3390/ijms20092129,10.3390/ijms20092129,10.3390/ijms20092129
10.1021/cb800025k,"Los, GV, Encell, LP, McDougall, MG, et al. HaloTag: a novel protein labeling technology for cell imaging and protein analysis. ACS Chem Biol 2008; 3: 373–82. PMID: 18533659",10.1021/cb800025k,10.1021/cb800025k,10.1021/cb800025k
10.1021/acs.bioconjchem.5b00191,"England, CG, Luo, H, Cai, W. HaloTag technology: a versatile platform for biomedical applications. Bioconjug Chem 2015; 26: 975–86. PMID: 25974629",10.1021/acs.bioconjchem.5b00191,10.1021/acs.bioconjchem.5b00191,10.1021/acs.bioconjchem.5b00191
10.1016/s1383-5742(00)00017-x,"Pegg, AE. Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res 2000; 462: 83–100. PMID: 10767620",10.1016/s1383-5742(00)00017-x,10.1016/s1383-5742(00)00017-x,10.1016/s1383-5742(00)00017-x
10.1093/emboj/19.7.1719,"Daniels, DS, Mol, CD, Arvai, AS, et al. Active and alkylated human AGT structures: a novel zinc site, inhibitor and extrahelical base binding. Embo J 2000; 19: 1719–30. PMID: 10747039",10.1093/emboj/19.7.1719,10.1093/emboj/19.7.1719,10.1093/emboj/19.7.1719
10.1038/nsmb791,"Daniels, DS, Woo, TT, Luu, KX, et al. DNA binding and nucleotide flipping by the human DNA repair protein AGT. Nat Struct Mol Biol 2004; 11: 714–20. PMID: 15221026",10.1038/nsmb791,10.1038/nsmb791,10.1038/nsmb791
10.1038/nbt765,"Keppler, A, Gendreizig, S, Gronemeyer, T, et al. A general method for the covalent labeling of fusion proteins with small molecules in vivo. Nat Biotechnol 2003; 21: 86–9. PMID: 12469133",10.1038/nbt765,10.1038/nbt765,10.1038/nbt765
,"Keppler, A, Pick, H, Arrivoli, C, et al. Labeling of fusion proteins with synthetic fluorophores in live cells. Proc Natl Acad Sci USA 2004; 10: 9955–9.",10.1073/pnas.0401923101,10.1073/pnas.0401923101,10.1073/pnas.0401923101
10.1016/s1074-5521(03)00068-1,"Juillerat, A, Gronemeyer, T, Keppler, A, et al. Directed evolution of O6-alkylguanine-DNA alkyltransferase for efficient labeling of fusion proteins with small molecules in vivo. Chem Biol 2003; 10: 313–7. PMID: 12725859",10.1016/s1074-5521(03)00068-1,10.1016/s1074-5521(03)00068-1,10.1016/s1074-5521(03)00068-1
10.1093/protein/gzl014,"Gronemeyer, T, Chidley, C, Juillerat, A, et al. Directed evolution of O6-alkylguanine-DNA alkyltransferase for applications in protein labeling. Protein Eng Des Sel 2006; 19: 309–16. PMID: 16638797",10.1093/protein/gzl014,10.1093/protein/gzl014,10.1093/protein/gzl014
10.1021/bi2016537,"Mollwitz, B, Brunk, E, Schmitt, S, et al. Directed evolution of the suicide protein O6-alkylguanine-DNA alkyltransferase for Increased reactivity results in an alkylated protein with exceptional stability. Biochemistry 2012; 51: 986–94. PMID: 22280500",10.1021/bi2016537,10.1021/bi2016537,10.1021/bi2016537
10.1016/j.chembiol.2008.01.007,"Gautier, A, Juillerat, A, Heinis, C, et al. An engineered protein tag for multiprotein labeling in living cells. Chem Biol 2008; 15: 128–36. PMID: 18291317",10.1016/j.chembiol.2008.01.007,10.1016/j.chembiol.2008.01.007,10.1016/j.chembiol.2008.01.007
10.1038/s41592-018-0017-z,"Vogel, P, Moschref Merkle, MM, Li, Q, et al. Efficient and precise editing of endogenous transcripts with SNAP-tagged ADARs. Nat Methods 2018; 15: 535–8. PMID: 29967493",10.1038/s41592-018-0017-z,10.1038/s41592-018-0017-z,10.1038/s41592-018-0017-z
10.1021/ja100117u,"Srikun, D, Albers, AE, Nam, CI, et al. Organelle-targetable fluorescent probes for imaging hydrogen peroxide in living cells via SNAP-Tag protein labeling. J Am Chem Soc 2010; 132: 4455–65. PMID: 20201528",10.1021/ja100117u,10.1021/ja100117u,10.1021/ja100117u
10.1021/ac501041w,"Abo, M, Minakami, R, Miyano, K, et al. Visualization of phagosomal hydrogen peroxide production by a novel fluorescent probe that is localized via SNAP-tag labeling. Anal Chem 2014; 86: 5983–90. PMID: 24862209",10.1021/ac501041w,10.1021/ac501041w,10.1021/ac501041w
10.1038/nchembio.1554,"Griss, R, Schena, A, Reymond, L, et al. Bioluminescent sensor proteins for point-of-care therapeutic drug monitoring. Nat Chem Biol 2014; 10: 598–603. PMID: 24907901",10.1038/nchembio.1554,10.1038/nchembio.1554,10.1038/nchembio.1554
10.1021/ja806634e,"Tomat, E, Nolan, EM, Jaworski, J, Lippard, SJ. Organelle-specific zinc detection using zinpyr-labeled fusion proteins in live cells. J Am Chem Soc 2008; 130: 15776–7. PMID: 18973293",10.1021/ja806634e,10.1021/ja806634e,10.1021/ja806634e
10.1021/ac100741t,"Kamiya, M, Johnsson, K. Localizable and highly sensitive calcium indicator based on a BODIPY fluorophore. Anal Chem 2010; 82: 6472–9. PMID: 20590099",10.1021/ac100741t,10.1021/ac100741t,10.1021/ac100741t
10.1002/anie.201005931,"Saccà, B, Meyer, R, Erkelenz, M, et al. Orthogonal protein decoration of DNA origami. Angew Chem Int Ed Engl 2010; 49: 9378–83. PMID: 21031395",10.1002/anie.201005931,10.1002/anie.201005931,10.1002/anie.201005931
10.1074/jbc.m111.308320,"Perugino, G, Vettone, A, Illiano, G, et al. Activity and regulation of archaeal DNA alkyltransferase: conserved protein involved in repair of DNA alkylation damage. J Biol Chem 2012; 287: 4222–31. PMID: 22167184",10.1074/jbc.a111.308320,10.1074/jbc.m111.308320,10.1074/jbc.a111.308320
10.1093/nar/gkv774,"Perugino, G, Miggiano, R, Serpe, M, et al. Structure-function relationships governing activity and stability of a DNA alkylation damage repair thermostable protein. Nucleic Acids Res 2015; 43: 8801–16. PMID: 26227971",10.1093/nar/gkv774,10.1093/nar/gkv774,10.1093/nar/gkv774
10.1007/s00792-015-0791-9,"Vettone, A, Serpe, M, Hidalgo, A, et al. A novel thermostable protein-tag: optimization of the Sulfolobus solfataricus DNA-alkyl-transferase by protein engineering. Extremophiles 2016; 20: 1–13. PMID: 26499124",10.1007/s00792-015-0791-9,10.1007/s00792-015-0803-9,10.1007/s00792-015-0791-9
10.1371/journal.pone.0185791,"Visone, V, Han, W, Perugino, G, et al. In vivo and in vitro protein imaging in thermophilic archaea by exploiting a novel protein tag. PloS One 2017; 12: e0185791. PMID: 28973046",10.1371/journal.pone.0185791,10.1371/journal.pone.0185791,10.1371/journal.pone.0185791
10.1155/2019/9848253,"Lo Gullo, G, Mattossovich, R, Perugino, G, et al. Optimization of an in vitro transcription/translation system based on Sulfolobus solfataricus cell lysate. Archaea 2019; 2019: 9848253. PMID: 30886540",10.1155/2019/9848253,10.1155/2019/9848253,10.1155/2019/9848253
10.1080/14756366.2018.1559161,"Merlo, R, Del Prete, S, Valenti, A, et al. An AGT-based protein-tag system for the labelling and surface immobilization of enzymes on E. coli outer membrane. J Enzyme Inhib Med Chem 2019; 34: 490–9. PMID: 30724623",10.1080/14756366.2018.1559161,10.1080/14756366.2018.1559161,10.1080/14756366.2018.1559161
10.1080/14756366.2019.1605991,"Del Prete, S, Merlo, R, Valenti, A, et al. Thermostability enhancement of the α-carbonic anhydrase from Sulfurihydrogenibium yellowstonense by using the anchoring-and-self-labelling-protein-tag system (ASL tag). J Enzyme Inhib Med Chem 2019; 34: 946–54. PMID: 31039618",10.1080/14756366.2019.1605991,10.1080/14756366.2019.1605991,10.1080/14756366.2019.1605991
10.1021/jm00101a028,"Moschel, RC, McDougall, MG, Dolan, ME, et al. Structural features of substituted purine derivatives compatible with depletion of human O6-alkylguanine-DNA alkyltransferase. J Med Chem 1992; 35: 4486–91. PMID: 1447749",10.1021/jm00101a028,10.1021/jm00101a028,10.1021/jm00101a028
10.1021/jm00029a005,"Chae, MY, McDougall, MG, Dolan, ME, et al. Substituted O6-benzylguanine derivatives and their inactivation of human O6-alkylguanine-DNA alkyltransferase. J Med Chem 1994; 37: 342–7. PMID: 8308861",10.1021/jm00029a005,10.1021/jm00029a005,10.1021/jm00029a005
10.1021/tx9700580,"Terashima, I, Kawate, H, Sakumi, K, et al. Substrate specificity of human O6-methylguanine-DNA methyltransferase for O6-benzylguanine derivatives in oligodeoxynucleotides. Chem Res Toxicol 1997; 10: 1234–9. PMID: 9403175",10.1021/tx9700580,10.1021/tx9700580,10.1021/tx9700580
10.1021/jm9708644,"McElhinney, RS, Donnelly, DJ, McCormick, JE, et al. Inactivation of O6-alkylguanine-DNA alkyltransferase. 1. Novel O6-(hetarylmethyl)guanines having basic rings in the side chain. J Med Chem 1998; 41: 5265–71. PMID: 9857094",10.1021/jm9708644,10.1021/jm9708644,10.1021/jm9708644
,"Sun, G, Fan, T, Zhang, N, et al. Identification of the structural features of guanine derivatives as MGMT inhibitors using 3D-QSAR modeling combined with molecular docking. Molecules 2016; 21: 823–44.",10.3390/molecules21070823,10.3390/molecules21070823,10.3390/molecules21070823
10.1021/ol201430x,"Zhang, CJ, Li, L, Chen, GYJ, et al. One-and two-photon live cell imaging using a mutant SNAP-Tag protein and its FRET substrate pairs. Org Lett 2011; 13: 4160–3. PMID: 21786765",10.1021/ol201430x,10.1021/ol201430x,10.1021/ol201430x
10.1016/j.ejmech.2016.10.067,"Huang, M, Deng, Z, Tian, J, Liu, T. Synthesis and biological evaluation of salinomycin triazole analogues as anticancer agents. Eur J Med Chem 2017; 127: 900–8. PMID: 27876192",10.1016/j.ejmech.2016.10.067,10.1016/j.ejmech.2016.10.067,10.1016/j.ejmech.2016.10.067
,"Leng, S, Qiao, Q, Miao, L, et al. A wash-free SNAP-tag fluorogenic probe based on the additive effects of quencher release and environmental sensitivity. Chem Commun 2017; 53: 6448–51.",10.1039/c7cc01483j,10.1039/c7cc01483j,10.1039/c7cc01483j
10.1021/ja034145s,"Kindermann, M, George, N, Johnsson, N, Johnsson, K. Covalent and selective immobilization of fusion proteins. J Am Chem Soc 2003; 125: 7810–1. PMID: 12822993",10.1021/ja034145s,10.1021/ja034145s,10.1021/ja034145s
10.1007/s00792-019-01134-3,"Mattossovich, R, Merlo, R, Fontana, A, et al. A journey down to hell: new thermostable protein-tags for biotechnology at high temperatures. Extremophiles 2020; 24: 81–91. PMID: 31555904",10.1007/s00792-019-01134-3,10.1007/s00792-019-01134-3,10.1007/s00792-019-01134-3
10.1016/j.bbrc.2018.04.139,"Rossi, F, Morrone, C, Massarotti, A, et al. Crystal structure of a thermophilic O6-alkylguanine-DNA alkyltransferase-derived self-labeling protein-tag in covalent complex with a fluorescent probe. Biochem Biophys Res Commun 2018; 500: 698–703. PMID: 29684348",10.1016/j.bbrc.2018.04.139,10.2210/pdb6ga0/pdb,10.1016/j.bbrc.2018.04.139
10.1002/jcc.20292,"Banks, JL, Beard, HS, Cao, Y, et al. Integrated Modeling Program, Applied Chemical Theory (IMPACT). J Comput Chem 2005; 26: 1752–80. PMID: 16211539",10.1002/jcc.20292,10.1002/jcc.20292,10.1002/jcc.20292
,"Toukmaji, AY, Board, JA, Jr,. Ewald summation techniques in perspective: a survey. Comput Phys Commun 1996; 95: 73–92.",10.1016/0010-4655(96)00016-1,10.1016/0010-4655(96)00016-1,10.1016/0010-4655(96)00016-1
10.1063/1.2018637,"Zielkiewicz, J. Structural properties of water: comparison of the SPC, SPCE, TIP4P, and TIP5P models of water. J Chem Phys 2005; 123: 104501. PMID: 16178604",10.1063/1.2178809,10.1063/1.2018637,10.1063/1.2018637
,"Martyna, GJ, Klein, ML, Tuckerman, M. Reversible multiple time scale molecular dynamics. J Chem Phys 1992; 97: 2635–43.",10.1063/1.463137,10.1063/1.463137,10.1063/1.463137
,"Evans, DJ, Holian, BL. The Nose–Hoover thermostat. J Chem Phys 1985; 3: 4069.",10.1063/1.449071,10.1063/1.449071,10.1063/1.449071
10.1042/bj20150833,"Miggiano, R, Perugino, G, Ciaramella, M, et al. Crystal structure of Mycobacterium tuberculosis O6-methylguanine-DNA methyltransferase protein clusters assembled on to damaged DNA. Biochem J 2016; 473: 123–33. PMID: 26512127",10.1042/bj20150833,10.1042/bj20150833,10.1042/bj20150833
10.1016/j.bbagen.2016.10.020,"Morrone, C, Miggiano, R, Serpe, M, et al. Interdomain interactions rearrangements control the reaction steps of a thermostable DNA alkyltransferase. Biochim Biophys Acta Gen Subj 2017; 1861: 86–96. PMID: 27777086",10.1016/j.bbagen.2016.10.020,10.1016/j.bbagen.2016.10.020,10.1016/j.bbagen.2016.10.020
10.1158/1078-0432.ccr-05-2198,"Ranson, M, Middleton, MR, Bridgewater, J, et al. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2006; 12: 1577–84. PMID: 16533784",10.1158/1078-0432.ccr-05-2198,10.1158/1078-0432.ccr-05-2198,10.1158/1078-0432.ccr-05-2198
10.1002/smll.201102284,"Colombo, M, Mazzucchelli, S, Montenegro, JM, et al. Protein oriented ligation on nanoparticles exploiting O6-alkylguanine-DNA transferase (SNAP) genetically encoded fusion. Small 2012; 8: 1492–7. PMID: 22431243",10.1002/smll.201102284,10.1002/smll.201102284,10.1002/smll.201102284
,"Song, X, Wang, C, Han, Z, et al. Terminal alkyne substituted O6-benzylguanine for versatile and effective syntheses of fluorescent labels to genetically encoded SNAP-tags. RSC Adv 2015; 5: 23646–9.",10.1039/c4ra17072e,10.1039/c4ra17072e,10.1039/c4ra17072e
10.1002/prot.24548,"Ferraris, DM, Spallek, R, Oehlmann, W, et al. Structure of Thermococcus litoralis Δ 1‐pyrroline‐2‐carboxylate reductase in complex with NADH and L‐proline. Proteins 2014; 82: 2268–74. PMID: 24615888",10.2210/pdb6t3e/pdb,10.2210/pdb6t3e/pdb,10.2210/pdb6t3e/pdb
10.1016/j.ab.2004.05.058,"Huber, W, Perspicace, S, Kohler, J, et al. SPR-based interaction studies with small molecular weight ligands using hAGT fusion proteins. Anal Biochem 2004; 333: 280–8. PMID: 15450803",10.1016/j.ab.2004.05.058,10.1016/j.ab.2004.05.058,10.1016/j.ab.2004.05.058
10.1021/acs.bioconjchem.6b00315,"Niesen, J, Sack, M, Seidel, M, et al. SNAP-Tag technology: a useful tool to determine affinity constants and other functional parameters of novel antibody fragments. Bioconjug Chem 2016; 27: 1931–41. PMID: 27391930",10.1021/acs.bioconjchem.6b00315,10.1021/acs.bioconjchem.6b00315,10.1021/acs.bioconjchem.6b00315
10.1016/j.bpj.2010.08.012,"Testa, I, Wurm, CA, Medda, R, et al. Multicolor fluorescence nanoscopy in fixed and living cells by exciting conventional fluorophores with a single wavelength. Biophys J 2010; 99: 2686–94. PMID: 20959110",10.1016/j.bpj.2010.08.012,10.1016/j.bpj.2010.08.012,10.1016/j.bpj.2010.08.012
,"Miggiano, R, Valenti, A, Rossi, F, et al. Every OGT is illuminated … by fluorescent and synchrotron lights. Int J Mol Sci 2017; 18: 2613–31.",10.3390/ijms18122613,10.3390/ijms18122613,10.3390/ijms18122613
10.1038/ncomms15352,"Zweerink, S, Kallnik, V, Ninck, S, et al. Activity-based protein profiling as a robust method for enzyme identification and screening in extremophilic Archaea. Nat Commun 2017; 8: 15352. PMID: 28480883",10.1038/ncomms15352,10.1038/ncomms15352,10.1038/ncomms15352
